



Preferred Drug List



Proprietary Name: Nplate™

Common Name: Romiplostim

PDL Category: Thrombopoietin Receptor Agonist

Comparable Products Promacta®	Preferred Drug List/ Recommended Drug List Status Recommended as Non-Preferred
---	--

Summary

Indications and Usage: Treatment of thrombocytopenia in splenectomized and non-splenectomized adults with chronic immune thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids or immunoglobulins.¹

Mechanism of Action: Increases platelet production through binding and activation of the thrombopoietin (TPO) receptor.¹

Dosage Forms: Injection: 250mcg and 500mcg

Recommended Dosage: Initial dose: 1mcg/kg SUBQ once weekly, adjust weekly in increments of 1mcg/kg to achieve platelet count of 50 x 10(9)/L or greater; MAX weekly dose is 10mcg/kg. Maintenance dose: If following 4 weeks of therapy at the maximum weekly dose of 10mcg/kg, the platelet count is not adequate to control bleeding, discontinue therapy and monitor platelets for 2 weeks.¹

Common Adverse Drug Reactions: Arthralgia, dizziness, insomnia, myalgia, pain in extremity, abdominal pain, shoulder pain, dyspepsia, paresthesia.¹

Contraindications: None determined.¹

Manufacturer: Amgen Inc.

Analysis: Nplate™ is the first thrombopoietin receptor agonist approved for long-term treatment for adult patients with chronic ITP. Two small studies of both splenectomized and non-splenectomized patients were used to gain FDA approval. The overall response rate was 83%, and patients were able to reduce or discontinue the use of rescue therapies. Only prescribers and patients enrolled in the Nplate™ NEXUS program can receive, prescribe, or administer Nplate™. Information regarding the Nplate™ NEXUS program is located at www.nplatenexus.com and is designed to be used as a source of education and support for healthcare professionals and patients. It is recommended that Nplate™ be added to the Preferred Drug List as a non-preferred drug to verify diagnosis, previous therapies, and enrollment in the NEXUS program.

IME Recommendation:

<input type="checkbox"/> Preferred Drug	<input type="checkbox"/> Recommended Drug
<input checked="" type="checkbox"/> Non-Preferred Drug	<input type="checkbox"/> Non-Recommended Drug
<input type="checkbox"/> Preferred Drug with Conditions	

1. Nplate™ [package insert]. Thousand Oaks, CA: Amgen Inc.; 2008.